Radionuclide antibody conjugates (RACs) and antibody-drug conjugates (ADCs) can function as biotherapeutic missiles in order to target cancer cells and destroy them. The advent of new technology platforms consisting of imaging modalities, drug design and radiochemistry will facilitate the personalised approach for cancer patient treatment programmes. The utilisation of radionuclides and cytotoxic drugs conjugated to biovectors can deliver a cytotoxic drug payload with the ability to emit alpha and/or beta particles in the vicinity of the tumour by binding onto the cancer cells surface antigens initiating cell death. This perspective aims to provide an insight into targeted therapies in the treatment of various cancerous disease states including breast cancer, prostate bone metastases, lymphoma and leukaemia.
Keywords: Radiometal, radionuclide antibody conjugates, antibody-drug conjugates (ADCs), biovectors, targeted alpha therapy, cancer.